JP2009519944A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519944A5 JP2009519944A5 JP2008545835A JP2008545835A JP2009519944A5 JP 2009519944 A5 JP2009519944 A5 JP 2009519944A5 JP 2008545835 A JP2008545835 A JP 2008545835A JP 2008545835 A JP2008545835 A JP 2008545835A JP 2009519944 A5 JP2009519944 A5 JP 2009519944A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dll4
- antagonist
- use according
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700041286 delta Proteins 0.000 claims description 14
- 101150109170 dll4 gene Proteins 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 101800003838 Epidermal growth factor Proteins 0.000 description 5
- 229940116977 epidermal growth factor Drugs 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75117305P | 2005-12-16 | 2005-12-16 | |
| US60/751,173 | 2005-12-16 | ||
| US77127606P | 2006-02-08 | 2006-02-08 | |
| US60/771,276 | 2006-02-08 | ||
| US78845606P | 2006-03-31 | 2006-03-31 | |
| US60/788,456 | 2006-03-31 | ||
| US83054306P | 2006-07-12 | 2006-07-12 | |
| US60/830,543 | 2006-07-12 | ||
| PCT/US2006/047848 WO2007070671A2 (en) | 2005-12-16 | 2006-12-15 | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519944A JP2009519944A (ja) | 2009-05-21 |
| JP2009519944A5 true JP2009519944A5 (enExample) | 2013-02-14 |
| JP5489465B2 JP5489465B2 (ja) | 2014-05-14 |
Family
ID=38163537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545835A Expired - Fee Related JP5489465B2 (ja) | 2005-12-16 | 2006-12-15 | Dll4アンタゴニストによって腫瘍増殖を阻害する治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080107648A1 (enExample) |
| EP (1) | EP1962895B2 (enExample) |
| JP (1) | JP5489465B2 (enExample) |
| AU (1) | AU2006326417B2 (enExample) |
| CA (1) | CA2630839C (enExample) |
| DK (1) | DK1962895T3 (enExample) |
| ES (1) | ES2400666T5 (enExample) |
| IL (1) | IL191810A (enExample) |
| NZ (1) | NZ568739A (enExample) |
| PL (1) | PL1962895T3 (enExample) |
| PT (1) | PT1962895E (enExample) |
| WO (1) | WO2007070671A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| US20080014196A1 (en) * | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| CA2654000A1 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| US7750124B2 (en) * | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| CL2007002989A1 (es) | 2006-10-19 | 2008-05-16 | Genentech Inc | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3. |
| AR063494A1 (es) * | 2006-10-19 | 2009-01-28 | Genentech Inc | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008076960A2 (en) * | 2006-12-18 | 2008-06-26 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| EP2120996A2 (en) * | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| US7544476B1 (en) * | 2008-07-11 | 2009-06-09 | Aveo Pharmaceuticals, Inc. | Identifying cancers sensitive to treatment with inhibitors of notch signaling |
| MX2011002837A (es) * | 2008-09-19 | 2011-07-29 | Medimmune Llc | Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos. |
| ES2541726T3 (es) * | 2008-10-01 | 2015-07-23 | F. Hoffmann-La Roche Ag | Anticuerpos anti-Notch2 y métodos de uso |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| UY32917A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| EP3485908B1 (en) * | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| WO2011068840A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| HRP20190044T1 (hr) | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| JP2015532272A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−2/Dll4結合剤および抗VEGF−R剤を含む薬学的組み合わせ |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| MX382902B (es) | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| IL293131A (en) | 2019-11-25 | 2022-07-01 | Univ California | Long-acting vegf inhibitors for intraocular neovascularization |
| WO2023063842A1 (ru) * | 2021-10-12 | 2023-04-20 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок |
| WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| ES2236634T3 (es) † | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| WO1998051799A1 (en) * | 1997-05-14 | 1998-11-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel differentiation inhibitor |
| CN1308347C (zh) † | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| JP4723140B2 (ja) † | 1999-06-08 | 2011-07-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された薬物動態特性を有する改変キメラポリペプチド |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| JP2005526701A (ja) * | 2001-11-14 | 2005-09-08 | ロランティス リミテッド | 内科療法 |
| CA2469204A1 (en) * | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| EP1537145A1 (en) | 2002-09-10 | 2005-06-08 | Lorantis Limited | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| WO2007028110A2 (en) | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US20080014196A1 (en) | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| CA2654000A1 (en) † | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
-
2006
- 2006-12-15 DK DK06848586.1T patent/DK1962895T3/da active
- 2006-12-15 NZ NZ568739A patent/NZ568739A/en not_active IP Right Cessation
- 2006-12-15 US US11/639,894 patent/US20080107648A1/en not_active Abandoned
- 2006-12-15 EP EP06848586.1A patent/EP1962895B2/en not_active Not-in-force
- 2006-12-15 PT PT68485861T patent/PT1962895E/pt unknown
- 2006-12-15 AU AU2006326417A patent/AU2006326417B2/en not_active Ceased
- 2006-12-15 CA CA2630839A patent/CA2630839C/en not_active Expired - Fee Related
- 2006-12-15 PL PL06848586T patent/PL1962895T3/pl unknown
- 2006-12-15 ES ES06848586.1T patent/ES2400666T5/es active Active
- 2006-12-15 JP JP2008545835A patent/JP5489465B2/ja not_active Expired - Fee Related
- 2006-12-15 WO PCT/US2006/047848 patent/WO2007070671A2/en not_active Ceased
-
2008
- 2008-05-29 IL IL191810A patent/IL191810A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519944A5 (enExample) | ||
| US20230203173A1 (en) | Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof | |
| CN108112254B (zh) | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 | |
| EP2773669B1 (en) | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs | |
| JP2015120706A5 (enExample) | ||
| JP2020513809A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| JP2019216719A (ja) | Cd47に対するヒト化及びキメラモノクローナル抗体 | |
| CN113906052B (zh) | 一种抗ceacam5的单克隆抗体及其制备方法和用途 | |
| WO2007070671A3 (en) | Therapeutic methods for inhibiting tumor growth with dll4 antagonists | |
| CN106659779A (zh) | 双特异性四价抗体及其制造和使用方法 | |
| JP2020524661A5 (enExample) | ||
| JP2019077731A (ja) | 改変した抗体組成物、それを作製および使用する方法 | |
| JP2012509881A5 (enExample) | ||
| JP2013523184A5 (enExample) | ||
| ME02484B (me) | Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 | |
| JP2009518024A5 (enExample) | ||
| JP2020536492A5 (enExample) | ||
| JP2013538566A5 (enExample) | ||
| JP2009522316A5 (enExample) | ||
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| CN111032689A (zh) | 抗爱帕琳肽抗体及其用途 | |
| JP2005535562A5 (enExample) | ||
| CN108513615B (zh) | 结合人大麻素1(cb1)受体的抗体 | |
| AU2015264550B2 (en) | Ang2 antibodies |